INTRODUCING

EQUIFLOW

 

what is EIPH?

One commonly accepted definition of EIPH describes it as a highly prevalent condition characterized by the presence of blood in the respiratory tract. It is caused by the rupture of the capillaries at the site of the blood gas barrier or alveoli. 

Responsible for facilitating the efficient exchange of gases while breathing, the alveoli are ultrathin making them predisposed to rupture because of their ultra thinness they are predisposed to rupture during extreme exertion and strenuous exercise, and a significant spike in blood pressure. The most extreme expression of EIPH is epistaxis.

Fig+3e.jpg
EIPH_horse.jpg
 
 
 
 
 

Pre-Clinical Studies

Extensive experimentation was carried out in the laboratory on nebulizing the EquiFlow™ protein solution. The results demonstrated the positive transferability via nebulization and encouraged us to try it in horses.

Safety Studies

Testing has shown that that the product poses no safety risks to horses when administered as directed. 

 
 

Clinical Field Trials

ReCellerate conducted a study that included 18 healthy and active competitive horses 

Teal Simple Comparison Chart (8).png
11.png
 

HERE’S WHAT WE FOUND

Teal Simple Comparison Chart (10).png
Teal Simple Comparison Chart (5).png
 
 

Advantages of EquiFlow

 
 

ReCellerate’s EquiFlow Presents a Healthy Non-Drug Option to Support the Reduction of Bleeding and Aid in the Natural Repair of the Damage Caused by Chronic EIPH

  • The diuretic drug Lasix (furosemide) is the most common product used to reduce the symptoms of EIPH.  It is not a treatment.

  • The prevalence of EIPH varies according to the type of examination performed and when it is conducted.  It is generally accepted however that at least 65% of all performance horses are affected at maximum exertion.

  • It has been estimated that almost every horse suffers from at least one episode of EIPH during its career.

  • It is also generally accepted that EIPH produces long-term extensive pulmonary damage, decreases performance, shortens a horse’s competitive career, and results in significant consequential economic loss for owners and trainers.

  • EquiFlow has been shown Not to be a performance enhancer

  • Testing has started in racing Camels in the Middle East

 
Teal Simple Comparison Chart (11).png
 
 
 

EquiFlow is still considered investigational and has yet to receive FDA drug approval.  However, these encouraging results suggest that the product may be an excellent option to support the reduction of EIPH in high-performance horses. More testing is planned for purposes of replicating these exciting results. 

Recellerate+Equiflow.jpg